Analysts Expect Biogen Inc (BIIB) to Announce $6.73 EPS

Analysts predict that Biogen Inc (NASDAQ:BIIB) will announce $6.73 earnings per share for the current quarter, Zacks reports. Twenty Seven analysts have made estimates for Biogen’s earnings. The highest EPS estimate is $7.65 and the lowest is $5.96. Biogen reported earnings per share of $5.26 during the same quarter last year, which indicates a positive year-over-year growth rate of 27.9%. The company is scheduled to report its next earnings report on Thursday, January 24th.

According to Zacks, analysts expect that Biogen will report full-year earnings of $25.82 per share for the current financial year, with EPS estimates ranging from $24.97 to $26.55. For the next fiscal year, analysts forecast that the firm will report earnings of $27.98 per share, with EPS estimates ranging from $25.10 to $30.76. Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side analysts that follow Biogen.

Biogen (NASDAQ:BIIB) last announced its earnings results on Tuesday, October 23rd. The biotechnology company reported $7.40 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $6.78 by $0.62. Biogen had a net margin of 24.08% and a return on equity of 38.70%. The business had revenue of $3.44 billion for the quarter, compared to analyst estimates of $3.33 billion. During the same quarter in the previous year, the firm posted $6.31 earnings per share. Biogen’s revenue was up 11.7% compared to the same quarter last year.

A number of equities analysts recently issued reports on BIIB shares. ValuEngine raised shares of Biogen from a “sell” rating to a “hold” rating in a research report on Tuesday, November 6th. JPMorgan Chase & Co. dropped their target price on shares of Biogen from $445.00 to $436.00 and set a “buy” rating on the stock in a research report on Wednesday, October 24th. Oppenheimer set a $400.00 target price on shares of Biogen and gave the stock a “buy” rating in a research report on Friday, October 19th. BidaskClub lowered shares of Biogen from a “buy” rating to a “hold” rating in a research report on Wednesday, October 3rd. Finally, Citigroup dropped their target price on shares of Biogen from $483.00 to $470.00 and set a “buy” rating on the stock in a research report on Monday, October 8th. Nine research analysts have rated the stock with a hold rating and twenty-one have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $382.58.

In other Biogen news, EVP Michael D. Ehlers sold 1,000 shares of Biogen stock in a transaction on Wednesday, September 26th. The shares were sold at an average price of $350.00, for a total transaction of $350,000.00. Following the sale, the executive vice president now owns 4,281 shares in the company, valued at $1,498,350. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 0.29% of the stock is owned by insiders.

Institutional investors and hedge funds have recently bought and sold shares of the business. Honkamp Krueger Financial Services Inc. acquired a new stake in shares of Biogen in the 3rd quarter valued at $103,000. LeJeune Puetz Investment Counsel LLC acquired a new stake in shares of Biogen in the 3rd quarter valued at $107,000. Adviser Investments LLC boosted its stake in shares of Biogen by 745.7% in the 2nd quarter. Adviser Investments LLC now owns 389 shares of the biotechnology company’s stock valued at $113,000 after purchasing an additional 343 shares in the last quarter. NEXT Financial Group Inc acquired a new stake in shares of Biogen in the 3rd quarter valued at $133,000. Finally, Harvest Fund Management Co. Ltd boosted its stake in shares of Biogen by 122.0% in the 3rd quarter. Harvest Fund Management Co. Ltd now owns 384 shares of the biotechnology company’s stock valued at $136,000 after purchasing an additional 211 shares in the last quarter. Hedge funds and other institutional investors own 86.41% of the company’s stock.

BIIB stock traded up $7.11 on Friday, reaching $333.72. 1,663,134 shares of the company were exchanged, compared to its average volume of 1,017,461. Biogen has a 12 month low of $249.17 and a 12 month high of $388.67. The firm has a market capitalization of $65.81 billion, a P/E ratio of 15.30, a price-to-earnings-growth ratio of 1.26 and a beta of 1.01. The company has a current ratio of 2.75, a quick ratio of 2.46 and a debt-to-equity ratio of 0.43.

Biogen Company Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for the treatment of neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis (MS); FUMADERM for the treatment of plaque psoriasis; and SPINRAZA to treat spinal muscular atrophy.

Featured Article: Price to Earnings Ratio (PE) Basics

Get a free copy of the Zacks research report on Biogen (BIIB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Biogen (NASDAQ:BIIB)

Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit